Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes

Peter Lang; Matt Vassar

doi:10.1038/s41585-025-01008-8

Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes

Research output: Contribution to journal › Comment/debate

Abstract

Prostate cancer is the most common cancer in men, yet disparities persist in screening, diagnosis and treatment among populations with low socioeconomic status. Minority groups face barriers to clinical trial inclusion including limited awareness and financial challenges. Promoting diversity in clinical trials is crucial for inclusivity, improving treatment efficacy and achieving equitable health outcomes in prostate cancer care.

Original language	English
Article number	e2410162
Journal	Nature Reviews Urology
DOIs	https://doi.org/10.1038/s41585-025-01008-8
State	Accepted/In press - 2025

Access to Document

10.1038/s41585-025-01008-8

Cite this

@article{1a062f5cf29144cd82d951e1b9dbd838,

title = "Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes",

abstract = "Prostate cancer is the most common cancer in men, yet disparities persist in screening, diagnosis and treatment among populations with low socioeconomic status. Minority groups face barriers to clinical trial inclusion including limited awareness and financial challenges. Promoting diversity in clinical trials is crucial for inclusivity, improving treatment efficacy and achieving equitable health outcomes in prostate cancer care.",

author = "Peter Lang and Matt Vassar",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2025.",

year = "2025",

doi = "10.1038/s41585-025-01008-8",

language = "English",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Research",

}

TY - JOUR

T1 - Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes

AU - Lang, Peter

AU - Vassar, Matt

N1 - Publisher Copyright: © Springer Nature Limited 2025.

PY - 2025

Y1 - 2025

N2 - Prostate cancer is the most common cancer in men, yet disparities persist in screening, diagnosis and treatment among populations with low socioeconomic status. Minority groups face barriers to clinical trial inclusion including limited awareness and financial challenges. Promoting diversity in clinical trials is crucial for inclusivity, improving treatment efficacy and achieving equitable health outcomes in prostate cancer care.

AB - Prostate cancer is the most common cancer in men, yet disparities persist in screening, diagnosis and treatment among populations with low socioeconomic status. Minority groups face barriers to clinical trial inclusion including limited awareness and financial challenges. Promoting diversity in clinical trials is crucial for inclusivity, improving treatment efficacy and achieving equitable health outcomes in prostate cancer care.

UR - http://www.scopus.com/inward/record.url?scp=85219659887&partnerID=8YFLogxK

U2 - 10.1038/s41585-025-01008-8

DO - 10.1038/s41585-025-01008-8

M3 - Comment/debate

AN - SCOPUS:85219659887

SN - 1759-4812

JO - Nature Reviews Urology

JF - Nature Reviews Urology

M1 - e2410162

ER -

Addressing diversity barriers in prostate cancer clinical trials for equitable healthcare outcomes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this